In the months since the outbreak of New Coronary pneumonia, scientists have been studying the virus carefully and developing possible treatment storts,media BGR reported. Some treatments will be immediately deployed in hospitals, such as Ridsywe and blood thinners. Others require more time, such as candidate vaccines that are undergoing clinical trials. But another form of COVID-19 therapy is beginning to emerge, and it seems to have shown promising results. At least two independent teams claim they have identified antibodies that can kill the new coronavirus, and the good news is that the compounds can be made into drugs that could soon be available to patients.
Hospitals around the world have been using the plasma of COVID-19 survivors to treat patients with weakened immune systems who are unable to produce their own new coronavirus antibodies. This strategy has also been effective for other infectious diseases and has been used for more than 100 years. Numerous reports indicate that the plasma of COVID-19 rehabilitation patients has saved many lives, but this treatment has a considerable drawback: it is not large enough to meet demand.
Researchers from the Netherlands, Israel and Japan have synthesized powerful antibodies that neutralise the virus in laboratory conditions. Their next step is to test these antibodies in humans in clinical trials. If the drugs are effective and safe, they may soon go into mass production as standard COVID-19 therapy.
A team at the University of Utrecht in the Netherlands has developed a monoclonal antibody called 47D11, which is simulated for human use in a counterpart in genetically modified mice infected with the virus. The target of 47D11 is SARS-CoV-2’s stingy glycoprotein (S protein), or a key component of the virus, which allows the virus to attach to ace2 receptors on cells. Without these proteins, the virus cannot replicate and the infection will be defeated. The interesting thing about 47D11 is that it can also fight the precursor of the new coronavirus, SARS.
“Such neutralizing antibodies have the potential to alter the infection process of the infected host, supporting the removal of the virus or protecting the exposure of uninfected individuals to the virus,” Berend-Jan Bosch, a researcher at the University of Utrecht, told the Guardian. Clinical trials will have to prove that this antibody is effective in humans. The study describing the new 47D11 antibody was published in the journal Nature.
The Guardian also reported on similar work by the Israel Institute of Biology, a state-run laboratory that claims to have created antibodies that can defeat the virus. Researchers have begun to patent the drug, which they hope will be produced on a large scale. Naftali Bennett, Israel’s defence minister, said the antibody was a “major breakthrough” and THAT IIBR scientists believe the normal testing process could be shortened to months. Israeli scientists have yet to name the antibody.
Researchers from Japan’s Beili University have teamed up with flower king and researchers from biotech start-up Epsilon Molecular Engineering to develop a candidate antibody they call VHHHHH, Nikkei reported. VHHHH is apparently derived from camel virus, which is only one-tenth the size of conventional antibodies and is less expensive to produce. After Epsilon determined the sequence information for VHHHH, Flower King used microorganisms to produce the antibody. According to the report, Flower King had previously used microorganisms to make detergents.
The researchers say the new antibody could suppress infection with the new coronavirus. It is unclear how long it will take for the drug to pass regulatory barriers and reach production, but clinical studies are still needed. Other countries are also studying their own monoclonal antibodies. South Korea plans to prepare a drug in the early years.